Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
Clearmind Medicine Inc. receives divisional patent approval from China National Intellectual Property Administration for regulating binge behaviors with primary amine aminoindan compounds, enhancing its IP protection in the psychedelic space. The company's innovative molecule, MEAI, shows promise in treating Alcohol Use Disorder and binge drinking.
The divisional patent approval in China for Clearmind Medicine Inc. represents a strategic enhancement of the company's intellectual property (IP) portfolio. This is a significant development because China is a major player in the global pharmaceutical market. The patent not only solidifies the company's protection over its primary amine aminoindan compounds but also potentially blocks competitors from entering the space with similar compounds.
Expanding the scope of their IP to cover compounds beyond their flagship molecule, MEAI, indicates a preemptive move to mitigate risk against future competition. It's also a sign of confidence in their research and the versatility of their chemical compounds. The broadening of their patent claims could serve as a deterrent for other entities considering the development of adjacent therapies, effectively reinforcing Clearmind's market position in the realm of psychedelic-derived therapeutics.
For stakeholders, this patent approval could translate into a more secure investment, as it implies a reduced risk of infringement litigation and a stronger defense against market encroachment. For a biotech firm like Clearmind, which operates in a highly competitive and research-intensive field, such patent wins are essential for attracting investment and partnerships.
Clearmind's announcement of the granted divisional patent in China is a noteworthy event for investors, as it indicates the company's ongoing commitment to expanding its global IP presence. The recognition of Clearmind's innovation in the psychedelic space by a major jurisdiction like China is likely to be viewed positively by the market.
Given the increasing interest in psychedelic therapy for mental health disorders, Clearmind's extensive patent portfolio positions it as a potential leader in this emerging field. The company's focus on Alcohol Use Disorder (AUD) and binge behaviors taps into a substantial market with a high unmet medical need. The prevalence of AUD and related conditions means that successful commercialization of their MEAI-based treatments could have a significant impact on revenue streams.
Investors will likely monitor the progression of MEAI from pre-clinical studies to clinical trials closely. Positive trial results could lead to substantial stock price appreciation, while any setbacks could have the opposite effect. Considering the long-term potential, if MEAI proves to be a viable treatment option, it could disrupt the current AUD treatment paradigm, which is a space traditionally dominated by counseling and medication-assisted therapies.
The therapeutic potential of Clearmind's MEAI molecule for treating binge behaviors and Alcohol Use Disorder is of particular interest in the field of addiction medicine. Binge drinking and AUD are pervasive issues with significant health, social and economic impacts. Current treatments have limitations and do not work for all patients, creating a demand for innovative approaches.
MEAI's unique mechanism, which reportedly reduces the desire to consume alcohol while providing a euphoric experience, could represent a paradigm shift in treatment options. If proven effective in clinical trials, it could offer a new avenue for patients who have not responded to traditional therapies. The safety profile will be a critical factor, as will the ability to integrate this therapy into existing treatment frameworks.
From a medical standpoint, the expansion of Clearmind's patent portfolio is a positive step towards protecting their research and development investments. It is essential, however, that the company continues to conduct rigorous clinical trials to establish the efficacy and safety of their compounds. The impact on patients' lives and the potential to reduce the societal burden of AUD and binge behaviors could be substantial if MEAI lives up to its promise.
03/19/2024 - 07:55 AM
A Novel Approach to Combatting Binge Behaviors with Groundbreaking Psychedelic Therapy
Tel Aviv, Israel / Vancouver, Canada, March 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has been granted divisional patent approval by the China National Intellectual Property Administration.
The divisional patent approval, previously announced, grants Clearmind a broader claim than patent application. Allowed claims directed to using a primary amine aminoindan compound to regulate a binge behavior. Covers primary amine aminoindan compounds besides 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule. This latest patent builds upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.
"We are proud to receive once again recognition of our innovative treatment for binge behaviors. We believe that this approval is a major milestone and significantly expands our IP protection as a leader in psychedelic-derived therapeutics,” said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani. “In various pre-clinical studies, carried out during the past 2 years, MEAI has demonstrated its ability to regulate binge behaviors, addiction and other mental health disorders. We believe these strong results demonstrate the significant potential of the MEAI molecule for various indications.”
MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and exerts a slight euphoric, alcohol-like experience with potential to change the lives of millions who struggle to drink in moderation. Clearmind’s MEAI-based flagship treatment focuses on Alcohol Use Disorder, which is incredibly common. It varies from mild to excessive and is characterized by a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences. Clearmind’s MEAI may also be used to treat binge drinking, which can be a deadly addiction for some.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of fifteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information visit: https://www.clearmindmedicine.com
Investor Relationsinvest@clearmindmedicine.com CMND@crescendo-ir.com
General InquiriesInfo@Clearmindmedicine.com www.Clearmindmedicine.com
F orward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its position as a leader in psychedelic-derived therapeutics and the significant potential of the MEAI molecule for various indications. In addition, the Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F filed with the SEC on January 29, 2024. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
What is the significance of Clearmind Medicine Inc. receiving divisional patent approval from China National Intellectual Property Administration?
The approval grants Clearmind broader claim than patent application for regulating binge behaviors with primary amine aminoindan compounds, enhancing its IP protection.
What is MEAI, the innovative molecule mentioned in the press release, used for?
MEAI is a new psychoactive molecule that reduces desire to consume alcoholic beverages and may treat Alcohol Use Disorder and binge drinking.
How many patents and pending patent applications does Clearmind Medicine Inc. currently have in major jurisdictions?
Clearmind has 27 granted patents and 24 pending patent applications across 15 patent families in major jurisdictions like the US, Europe, China, and India.
What is Clearmind's MEAI-based flagship treatment focused on?
Clearmind's MEAI-based flagship treatment focuses on Alcohol Use Disorder, helping individuals who struggle to drink in moderation.
